[EN] O-ALKYL TRIAZOLYL CARBAMATES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE (FAAH) [FR] CARBAMATES DE O-ALKYLTRIAZOLYLE EN TANT QU'INHIBITEURS DE L'HYDROLASE DES AMIDES D'ACIDES GRAS (FAAH)
Supporting-Electrolyte-Free Anodic Oxidation of Oxamic Acids into Isocyanates: An Expedient Way to Access Ureas, Carbamates, and Thiocarbamates
作者:Alessia Petti、Corentin Fagnan、Carlo G. W. van Melis、Nour Tanbouza、Anthony D. Garcia、Andrea Mastrodonato、Matthew C. Leech、Iain C. A. Goodall、Adrian P. Dobbs、Thierry Ollevier、Kevin Lam
DOI:10.1021/acs.oprd.1c00112
日期:2021.12.17
report a new electrochemical supporting-electrolyte-free method for synthesizing ureas, carbamates, and thiocarbamates via the oxidation of oxamic acids. This simple, practical, and phosgene-free route includes the generation of an isocyanate intermediate in situ via anodic decarboxylation of an oxamic acid in the presence of an organic base, followed by the one-pot addition of suitable nucleophiles to afford
我们报告了一种新的电化学无负载电解质方法,用于通过草酸氧化合成尿素、氨基甲酸酯和硫代氨基甲酸酯。这种简单、实用且无光气的路线包括在有机碱存在下通过草酸的阳极脱羧原位生成异氰酸酯中间体,然后一锅加入合适的亲核试剂以提供相应的尿素,氨基甲酸酯和硫代氨基甲酸酯。此程序适用于不同的胺、醇和硫醇。此外,当使用单程连续电化学流动条件并且该反应在碳石墨 C gr /C gr 在流动池中,可以在 6 分钟的停留时间内以高产率获得尿素化合物,解锁在批量条件下无法访问的底物,同时易于扩展。
N-terminus to C-terminus metallacyclicpeptides employing tungsten–alkyne coordination
作者:Timothy P. Curran、Richard S.H. Yoon、Brian R. Volk
DOI:10.1016/j.jorganchem.2004.09.062
日期:2004.12
The capacity of using tungsten-alkyne coordination to form metallacyclicpeptides was examined. Dialkynyl species 1, 2 and 3 were prepared. 1 is a dialkyne derivative of ammonia, 2 is a dialkyne derivative of alanine, while 3 is a dialkyne derivative of the dipeptide alanylalanine. In 2 and 3 the two alkyne groups were appended at the N- and C-termini. The N-terminal alkyne was prepared by acylating the N-terminal amine with propargylchloroformate. The C-terminal alkyne was introduced by acylating the C-terminal carboxylic acid with propargylamine. Outcomes of metallacyclization reactions were assessed using H-1 NMR spectroscopy and electrospray positive ion mass spectrometry. Both 2 and 3 underwent successful cyclization to yield the metallacyclicpeptides 16 and 17, respectively. However, 1 did not cyclize; instead, it formed a variety of acyclic and cyclic oligomeric tungstenbis(alkyne) species. The failure of 1 to cyclize is attributed to its inability to position its two alkyne groups parallel to each other and spaced 6.5 A apart. The H-1 NMR spectra for 16 and 17 show that these metallacyclicpeptides exist as a complex mixture of isomers that differ in how the ligands are positioned around the tungsten center. At elevated temperatures metallcycliepeptide 17 will rapidly interconvert between the various isomers. In contrast, 16 does not readily interconvert between isomers, even at elevated temperatures. That 16 does not rapidly interconvert between isomers, even at 90degreesC, is attributed to the tight packing and limited conformational freedom of this metallacyclicpeptide. (C) 2004 Elsevier B.V. All rights reserved.
<i>O</i>-(Triazolyl)methyl Carbamates as a Novel and Potent Class of Fatty Acid Amide Hydrolase (FAAH) Inhibitors
Inhibition of fattyacidamidehydrolase (FAAH) activity is under investigation as a valuable strategy for the treatment of several disorders, including pain and drug addiction. A number of potent FAAH inhibitors belonging to different chemical classes have been disclosed to date; O‐aryl carbamates are one of the most representative families. In the search for novel FAAH inhibitors, a series of O‐(1
[EN] O-ALKYL TRIAZOLYL CARBAMATES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE (FAAH)<br/>[FR] CARBAMATES DE O-ALKYLTRIAZOLYLE EN TANT QU'INHIBITEURS DE L'HYDROLASE DES AMIDES D'ACIDES GRAS (FAAH)
申请人:FOND ISTITUTO ITALIANO DI TECNOLOGIA
公开号:WO2015007613A1
公开(公告)日:2015-01-22
The present invention provides compounds of formula I and pharmaceutical compositions for inhibiting fatty acid amide hydrolase (FAAH). Inhibition of FAAH is contemplated as a method to sustain the levels of the fatty acid ethanolamides arachidonoylethanolamide (AEA), palmitoylethanolamide (PEA), and oleoylethanolamide (OEA), three substrates of FAAH, in conditions characterized byreduced concentrations of AEA, PEA and OEA. The invention also provides methods for treating disorders in which decreased levels of AEA, PEA and OEA are associated with the disorder.